Category Archives: Business of Biotech

The BIO/Thomson Reuters Investor Perception Study is an in-depth assessment of Wall Street’s views of the biotech industry, its current challenges, its relative valuation, and the outlook for 2009. The analysis aims to provide BIO members with an insider’s perspective on what the investment community values in the current economic climate and help foster more effective communication between company management, shareholders, and potential investors.